SAN DIEGO, March 12 /PRNewswire-FirstCall/ -- SpectraScience, Inc. announced today that an abstract of its clinical study for Barrett’s esophagus has been chosen by the American Society of Gastrointestinal Endoscopy (ASGE) for a poster session presentation at the annual international clinical/scientific meeting in Washington D.C. in May. The study was submitted to the Society for peer review by the study investigators. The investigators included the Mayo Clinic, Rochester, MN, Minnesota Gastroenterology, PA, Minneapolis, MN, Veterans Administration Medical Center, San Diego, CA, and the Veteran’s Administration Boston Healthcare Center, Boston, MA.
According to Jim Hitchin, President of SpectraScience, “We are pleased that the ASGE has selected our study to be highlighted at this year’s meeting. The results of our study demonstrates the WavStat Optical Biopsy System is capable of determining if tissue is normal or pre-cancerous with a high degree of sensitivity and specificity. If the tissue is abnormal, it can be removed during the same procedure. Furthermore, the margins of the diseased tissue can be mapped so that all tissue is removed. It is important for us as we enter the final phase of the study to be recognized by such a prestigious group of scientists and clinical gastroenterologists.”
The WavSTAT(TM) is used by physicians to diagnose tissue to determine if it is normal, pre-cancerous, or cancerous within one second. The WavSTAT(TM) System is currently approved by the FDA for use in detecting cancer in the colon. A new application for detecting pre-cancers in the throat, sometimes called Barrett’s esophagus, is being tested in a clinical trial mentioned above. Cancer of the esophagus is more than 90% fatal and may develop as a result of chronic heartburn or GERD. Esophageal cancer is growing five times faster than all other cancers.”
This news release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience’s actual results to differ materially from the results discussed in the forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, the Form 10-KSB and in SpectraScience’s other reports filed with the Securities and Exchange Commission (“SEC”) that attempt to advise interested parties of the risks and factors that may affect SpectraScience’s business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-KSB and other documents.
For further information contact Jim Hitchin at (858) 847-0200 x 201. www.spectrascience.com
SpectraScience, Inc.
CONTACT: Jim Hitchin of SpectraScience, Inc., +1-858-847-0200, ext. 201
